Core Viewpoint - UBI, a shareholder holding 10.52% of Shenyuan Biological (688098), plans to reduce its stake due to funding needs for clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Group 1: Shareholder Actions - UBI intends to reduce its holdings by up to 4.1064 million shares through centralized bidding, representing 1% of the total share capital [1] - Additionally, UBI plans to reduce its holdings by up to 8.2129 million shares through block trading, accounting for 2% of the total share capital [1]

证券代码：688098 证券简称：申联生物 公告编号：2025-037 申联生物医药(上海)股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，美国联合生物医药公司（UNITED BIOMEDICAL, INC. 以下简称"UBI"）持有申联生物医药（上海）股份有限公司（以下简称"公司" 或"申联生物"）43,199,898 股股份，占公司总股本的 10.52%。上述股份来源为 公司首次公开发行股票并上市前取得，且已于 2020 年 10 月 28 日后上市流通。 减持计划的主要内容 股东 UBI 因推进其阿尔茨海默症合成肽疫苗等原研创新药的临床试验、商 业化布局及与中国的合作伙伴加速与合成肽有关的生产制造基地的建设等而需 资金投入，拟自本公告披露之日起 15 个交易日之后的 3 个月内以通过上海证券 交易所交易系统以集中竞价交易方式减持本公司股份 4,106,440 股，不超过本公 司股份总数的 1.00%；以大 ...

Core Points - The core point of the announcement is that United BioPharma, a US-based company, holds 43.1999 million shares of Shenlian Bio, accounting for 10.52% of the total shares [1] Summary by Category Shareholding and Reduction Plan - United BioPharma plans to reduce its holdings due to funding needs, with a proposed reduction period from November 13, 2025, to February 12, 2026 [1] - The company intends to sell up to 4.1064 million shares through centralized bidding, representing 1.00% of the total shares [1] - Additionally, it plans to reduce up to 8.2129 million shares through block trading, which accounts for 2.00% of the total shares [1] - The total reduction will not exceed 12.3193 million shares, which is a maximum of 3% of the total shares, all of which were acquired before the IPO [1]

Core Viewpoint - UBI, a major shareholder of Shenlian Bio, plans to reduce its stake by up to 3% to fund clinical trials and commercialization of innovative drugs, including an Alzheimer's peptide vaccine [1] Summary by Categories Shareholder Actions - UBI intends to reduce its holdings by a total of up to 12,319,300 shares, which represents 3% of Shenlian Bio's total share capital [1] - The reduction will occur through two methods: a centralized bidding transaction for up to 4,106,400 shares and a block trade for up to 8,212,900 shares [1] Timeline - The planned reduction period is from November 13, 2025, to February 12, 2026 [1] Purpose of Reduction - The funds from the share reduction will be used to support the clinical trials and commercialization of the Alzheimer's peptide vaccine and to accelerate the construction of manufacturing bases in collaboration with partners in China [1]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.02% on October 21, with Bioworks leading the drop. Meanwhile, the Shanghai Composite Index rose by 1.36% and the Shenzhen Component Index increased by 2.06% [1]. Group 1: Market Performance - The animal health sector's performance was mixed, with individual stocks showing varying degrees of increase and decrease. Notably, the top gainers included: - Driving Force (4.50% increase) [1] - Dayu Biological (3.46% increase) [1] - Yongshun Biological (2.06% increase) [1] - Conversely, Bioworks saw a decline of 2.10%, leading the losses in the sector [2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector indicated a net outflow of 151 million yuan from institutional investors, while retail investors saw a net inflow of 116 million yuan [2]. - The capital flow for individual stocks showed significant movements, with: - Key stock, Bioworks, experiencing a net outflow of 6.46 million yuan from institutional investors [3]. - Retail investors contributed a net inflow of 7.59 million yuan to Zhongmu Co. [3]. Group 3: Individual Stock Analysis - The following stocks had notable capital flows: - KQ Biological had a net inflow of 1.83 million yuan from institutional investors [3]. - ST Green Health faced a net outflow of 4.37 million yuan from institutional investors [3]. - The stock of Rui Pu Biological saw a net inflow of 17.22 million yuan from retail investors despite a net outflow from institutional investors [3].

Market Overview - The animal health sector increased by 0.81% on October 20, with Xianfeng Holdings leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Xianfeng Holdings (002141) closed at 4.06, up 5.45% with a trading volume of 588,700 shares and a turnover of 237 million yuan [1] - Other notable stocks included ST Lvkang (002868) at 28.36, up 5.00%, and Biological Shares (600201) at 10.95, up 1.48% [1] - The overall trading volume and turnover for the animal health sector were significant, indicating active market participation [1] Capital Flow - The animal health sector saw a net inflow of 31.5863 million yuan from institutional investors, while retail investors experienced a net outflow of 10.9434 million yuan [2] - The main capital inflow was primarily directed towards Xianfeng Holdings, which had a net inflow of 28.5381 million yuan [3] - Conversely, stocks like Shunlian Biological (688088) and ST Lvkang experienced net outflows from retail investors, indicating a shift in investor sentiment [3]

Market Overview - The Shanghai Composite Index closed at 3839.76 points, below the five-day moving average, with a decline of 1.95% [1] - The total trading volume of A-shares reached 1,954.408 billion yuan [1] Stocks Performance - A total of 152 A-shares broke through the five-day moving average today [1] - Stocks with significant deviation rates include: - Haixia Innovation (14.94%) - Shenlian Biology (8.07%) - Huabang Health (7.93%) [1] - Stocks with minor deviation rates that just crossed the five-day moving average include Tianyu Co., Suhao Fashion, and Longquan Co. [1] Notable Stocks - Top stocks with the highest deviation rates on October 17: - Haixia Innovation: +19.96% with a turnover rate of 18.39%, five-day moving average at 5.07 yuan, latest price at 5.83 yuan [1] - Shenlian Biology: +10.65% with a turnover rate of 7.78%, five-day moving average at 10.58 yuan, latest price at 11.43 yuan [1] - Huabang Health: +10.11% with a turnover rate of 8.30%, five-day moving average at 4.64 yuan, latest price at 5.01 yuan [1]

Core Viewpoint - The innovative drug concept stocks continue to be active, with significant gains observed in several companies [2] Company Performance - Huabang Health reached the daily limit increase in stock price [2] - Other companies such as Shenlian Bio, Shutaishen, Chenxin Pharmaceutical, Weikang Pharmaceutical, and Hite Bio also experienced upward movement in their stock prices [2]

Core Viewpoint - The animal health sector experienced a decline of 0.85% on October 16, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.1%, while the Shenzhen Component Index fell by 0.25 [1]. Group 1: Market Performance - The closing price of *ST Lvkang was 27.48, with an increase of 5.01%, while other stocks in the sector showed mixed results [1]. - The total trading volume for the animal health sector was significant, with *ST Lvkang recording a volume of 14,900 hands and a transaction amount of 40.81 million yuan [1]. - The overall market saw a net outflow of 126 million yuan from the animal health sector, with retail investors contributing a net inflow of 91.62 million yuan [2]. Group 2: Individual Stock Analysis - *ST Lvkang had a net inflow of 5.23 million yuan from major funds, while Xianfeng Holdings saw a net outflow of 3.36 million yuan [3]. - The stock of RuiPu Bio had a significant net outflow of 25.44 million yuan from major funds, despite a retail net inflow of 39.62 million yuan [3]. - The stock of HaiLi Bio experienced a net outflow of 4.47 million yuan from major funds, with a retail net inflow of 2.64 million yuan [3].